메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 31, Issue 1, 2013, Pages 166-167
Improvement in progression-free survival in OCEANS bevacizumab arm: A critical point of view
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; TRABECTEDIN;
EID: 84871739036     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.6237     Document Type: Letter
Times cited : (8)
References (7)
  • 1
    • 84861736119 scopus 로고    scopus 로고
    • OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    • Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 2039-2045
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3
  • 2
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 3
    • 79956076619 scopus 로고    scopus 로고
    • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
    • Rustin GJ, Vergote I, Eisenhauer E, et al: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419-423, 2011
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 419-423
    • Rustin, G.J.1    Vergote, I.2    Eisenhauer, E.3
  • 4
    • 79960441482 scopus 로고    scopus 로고
    • Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
    • Herzog TJ, Vermorken JB, Pujade-Lauraine E, et al: Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. Gynecol Oncol 122:350-355, 2011
    • (2011) Gynecol Oncol , vol.122 , pp. 350-355
    • Herzog, T.J.1    Vermorken, J.B.2    Pujade-Lauraine, E.3
  • 5
    • 77955491837 scopus 로고    scopus 로고
    • Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
    • Monk BJ, Herzog TJ, Kaye SB, et al: Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107-3114, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 3107-3114
    • Monk, B.J.1    Herzog, T.J.2    Kaye, S.B.3
  • 6
    • 79953863317 scopus 로고    scopus 로고
    • Big costs for little gain in ovarian cancer
    • Hensley ML: Big costs for little gain in ovarian cancer. J Clin Oncol 29:1230-1232, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 1230-1232
    • Hensley, M.L.1
  • 7
    • 79953893326 scopus 로고    scopus 로고
    • At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis
    • Cohn DE, Kim KH, Resnick KE, et al: At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29:1247-1251, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 1247-1251
    • Cohn, D.E.1    Kim, K.H.2    Resnick, K.E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.